House passes bill to reauthorize FDA user fee programs
The House yesterday voted 392-28 to pass legislation (H.R. 7667) that would reauthorize Food and Drug Administration user fee programs, which provide funding for the agency to review drugs, devices and biologics. Among other provisions, the bipartisan bill would include drugs on the FDA’s shortages list in a pilot program to designate advanced manufacturing technologies. The Senate Health, Education, Labor, and Pensions Committee will mark up their version of the bill Tuesday.
Related News Articles
Headline
The Food and Drug Administration May 23 announced that Medline Industries, a firm marketing and distributing Chinese-manufactured plastic syringes within the U…
Headline
The Food and Drug Administration yesterday announced an import alert for plastic syringes manufactured by two China-based manufacturers, in addition to…
Headline
The Food and Drug Administration May 9 released final guidance clarifying the definition of “remanufacturing” for reusable medical devices needing…
Headline
U.S. health care organizations should immediately transition away from using certain unauthorized plastic syringes made in China by Jiangsu Caina Medical Co.…
Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
In updated guidance for makers of medical devices labeled as sterile, the Food and Drug Administration Jan. 8 listed vaporized hydrogen peroxide as an…